(VIANEWS) – The Market ended the session with ULTIMOVACS (ULTI.OL) jumping 15.79% to kr8.80 on Tuesday, after four successive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.92% to kr1,279.21, following the last session’s downward trend on what was a somewhat up trend exchanging session today.
ULTIMOVACS’s last close was kr7.60, 95.74% under its 52-week high of kr178.60.
About ULTIMOVACS
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers. Its lead product candidate is UV1, a peptide-based cancer vaccine that induces a specific T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ULTIMOVACS has a trailing twelve months EPS of kr-6.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.94%.
Moving Average
ULTIMOVACS’s value is way under its 50-day moving average of kr130.87 and way under its 200-day moving average of kr101.89.
Yearly Top and Bottom Value
ULTIMOVACS’s stock is valued at kr8.80 at 21:34 EST, way below its 52-week low of kr67.90.
Volatility
ULTIMOVACS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.79%, a negative 1.47%, and a positive 2.79%.
ULTIMOVACS’s highest amplitude of average volatility was 5.79% (last week), 4.37% (last month), and 2.79% (last quarter).
More news about ULTIMOVACS (ULTI.OL).
